<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684708</url>
  </required_header>
  <id_info>
    <org_study_id>EuroNet-PHL-C2</org_study_id>
    <nct_id>NCT02684708</nct_id>
  </id_info>
  <brief_title>Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents</brief_title>
  <official_title>European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Euronet Worldwide</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with&#xD;
      the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical&#xD;
      Hodgkin lymphoma without compromising cure rates and to investigate a chemotherapy&#xD;
      intensification randomisation in intermediate and advanced classical Hodgkin lymphoma to&#xD;
      compensate for reduction in radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EuroNet-PHL-C2 is a comprehensive treatment strategy for all first line classical Hodgkin&#xD;
      Lymphoma (cHL) patients under 18 years (under 25 years in UK, Italy and France). The overall&#xD;
      strategy is risk stratified (defining chemotherapy) and response adapted (defining&#xD;
      radiotherapy) to tailor the amount of treatment to the individual patient and decrease long&#xD;
      term complications.&#xD;
&#xD;
        -  Radiotherapy indication will be restricted. Patients with a negative PET scan after two&#xD;
           cycles of OEPA chemotherapy (Early Response Assessment - ERA) will not receive&#xD;
           radiotherapy. The threshold for negative PET scan at ERA shifts from the previously used&#xD;
           Deauville 1 and 2 = negative (as in the C1 trial) to Deauville 1, 2 and 3 = negative,&#xD;
           thereby increasing the number of negative patients without indication for RT.&#xD;
&#xD;
        -  Chemotherapy Randomisation&#xD;
&#xD;
      All intermediate (TL-2) and advanced stage (TL-3) patients will be randomised between&#xD;
      respectively 2 or 4 standard COPDAC-28 or intensified DECOPDAC-21 consolidation chemotherapy&#xD;
      cycles. To avoid delayed consolidation, randomisation has to be performed before ERA and as&#xD;
      soon as the TL-assignment is confirmed by central review. Therefore two randomised&#xD;
      sub-studies arise based on the ERA PET response:&#xD;
&#xD;
      Patients with adequate response at ERA do not receive radiotherapy - a randomised controlled&#xD;
      chemotherapy comparison to show that intensified DECOPDAC-21 consolidation chemotherapy&#xD;
      improves EFS as compared to standard COPDAC-28&#xD;
&#xD;
      Patients with inadequate response at ERA - a randomised controlled chemotherapy-radiotherapy&#xD;
      comparison - to show that DECOPDAC-21 combined with radiotherapy restricted to sites that&#xD;
      remain FDG-PET positive at the end of all chemotherapy (Late response assessment - LRA) has&#xD;
      comparable EFS compared to COPDAC-28 plus standard involved node radiotherapy as in the C1&#xD;
      trial.&#xD;
&#xD;
        -  Risk stratification is refined Former treatment groups (TG) of the EuroNet-PHL-C1 trial&#xD;
           are reassigned into treatment levels (TL) by shifting early stage patients (former TG-1)&#xD;
           with risk factors into TL-2.&#xD;
&#xD;
        -  Semi-quantitative 'qPET' Results of semi-quantitative qPET are formally integrated into&#xD;
           the response assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 1, 2015</start_date>
  <completion_date type="Anticipated">September 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time from treatment start until relapse/progression, secondary malignancy or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time from treatment start until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Time from treatment start until relapse/progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTC (common toxicity criteria) grading during any individual treatment element including assessment of osteonecrosis</measure>
    <time_frame>5 years</time_frame>
    <description>Toxicity assessment according to CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from day of PET imaging until decision on response category at ERA or LRA, respectively</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of Imaging (CT,MRI and PET-CT) acquisition,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from last day of chemotherapy to first day of radiotherapy in patients with radiotherapy indication</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of chemo-and radiotherapy delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from last dose of prednisone/prednisolone in OEPA to start of the first consolidation cycle</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of chemotherapy delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2200</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>COPDAC-28</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cyclophosphamide, vincristine, prednisone, dacarbazine; cyclophosphamide 500 mg/m2, per infusion on day 1 + 8; vincristine 1.5 mg/m2 intravenously (capping dose 2 mg) on day 1 + 8 and prednisone 40 mg/m2/day by mouth divided into 3 doses (capping dose 80 mg/day) on day 1 - 15 and dacarbazine 250 mg/m2 infusion on day 1 - 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DECOPDAC-21</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with intermediate and advanced stages will be randomized after the induction therapy to receive either COPDAC-28 standard consolidation or the intensified DECOPDAC-21. cyclophosphamide dose augmented to 625 mg/m2 and adminstered per infusion on day 1 and day 2; vincristine dose not changed; prednisone 40 mg/m2/day by mouth on day 1 - 8 (no capping dose prescribed), i.e. dose-reduction; dacarbazine dose not changed; etoposide infusion100 mg/m2/day on day 1 - 3 and doxorubicine 25 mg/m2 per infusion on day 1as additional drugs in comparison to active comparator; cycle is administered as 21 days instead of 28 days-cycle for intensification</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide, vincristine, prednisone, dacarbazine</intervention_name>
    <description>28-day chemotherapy cycle</description>
    <arm_group_label>COPDAC-28</arm_group_label>
    <other_name>CYC, VCR, PRED, DTIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclo, vcr, pred, dacarb,etop and doxo</intervention_name>
    <description>21-day chemotherapy cycle</description>
    <arm_group_label>DECOPDAC-21</arm_group_label>
    <other_name>CYC, VCR, PRED, DTIC, ETO, DOXO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  histologically confirmed primary diagnosis of classical Hodgkin's lymphoma&#xD;
&#xD;
          -  patients under 18 years of age on the date of written informed consent. In specialized&#xD;
             Teenage and Young Adult (TYA) units in France, Italy and UK patients up to under 25&#xD;
             years of age can also be enrolled. Lower age limits will be country specific according&#xD;
             to national laws or formal insurance requirements that may preclude very young&#xD;
             patients.&#xD;
&#xD;
          -  written informed consent of the patient and/or the patient's parents or guardian&#xD;
             according to national laws&#xD;
&#xD;
          -  negative pregnancy test within 2 weeks prior to starting treatment for female patients&#xD;
             with childbearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior chemotherapy or radiotherapy for other malignancies&#xD;
&#xD;
          -  pre-treatment of Hodgkin's lymphoma (except for 7-10 days steroid pre-phase of a large&#xD;
             mediastinal tumour)&#xD;
&#xD;
          -  diagnosis of lymphocyte-predominant Hodgkin's lymphoma&#xD;
&#xD;
          -  other (simultaneous) malignancies&#xD;
&#xD;
          -  contraindication or known hypersensitivity to study drugs&#xD;
&#xD;
          -  severe concomitant diseases (e.g. immune deficiency syndrome)&#xD;
&#xD;
          -  known HIV-positivity&#xD;
&#xD;
          -  residence outside the participating countries where long term follow-up cannot be&#xD;
             guaranteed&#xD;
&#xD;
          -  pregnancy and/or lactation&#xD;
&#xD;
          -  patients who are sexually active and are unwilling to use adequate contraception&#xD;
             during therapy and for one month after last trial treatment&#xD;
&#xD;
          -  current or recent (within 30 days prior to date of written informed consent) treatment&#xD;
             with another investigational drug or participation in another interventional clinical&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Koerholz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Justus-Liebig University of Giessen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Children's Hospital and Monash Medical Centre Royal Children's Hospital</name>
      <address>
        <city>Victoria Park</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anna Kinderspital</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paediatric haemato-oncology, University Hospitals of Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dpt. of Pediatric Hematology and Oncology, Faculty Hospital Motol</name>
      <address>
        <city>Prague</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Hematology/Oncology (5054) The Child and Youth Clinic, University Hospital of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncohématologie, Hopital d'Ènfants Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus Liebig University of Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady's Children's Hospital, Crumlin</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv University Schneider Children's Medical Center of Israel The Rina Zaizov Pediatric Hematology Oncology Division</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Radiotherapy and Youth Area Unit C.R.O. - Centro di Riferimento Oncologico IRCCS</name>
      <address>
        <city>Aviano</city>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Máxima Center for pediatric oncology</name>
      <address>
        <city>Utrecht</city>
        <zip>3508</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Starship Blood and Cancer Centre, Starship Children's Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medical Oncology Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Head of Department of Pediatric Oncology and Hematology, Polish-American Pediatric Institute, Jagiellonian University Medical Faculty</name>
      <address>
        <city>Kraków</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Pediatric Oncology University Children's Hospital</name>
      <address>
        <city>Bratislava</city>
        <zip>83340</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sección de Onco-Hematología Pediátrica Hospital Universitario Virgen Macarena y Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology &amp; Oncology Children´s University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV - Centre Hospitalier Universitaire Vaudois = LS, Départment femme - meré - enfant, Service de pédiatrie, Unité d'hématologie-oncologie pédiatrique</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=EuroNet-PHL-C2</url>
    <description>Hodgkin lymphoma treatment in children and adolescents</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2016</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

